Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogenei...
Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogeneic stem cell transplantation
About this item
Full title
Author / Creator
Binkert, L , Medinger, M , Halter, J P , Heim, D , Gerull, S , Holbro, A , Lengerke, C , Weisser, M and Passweg, J R
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
In vivo
T-cell depletion with anti-thymocyte globulin (ATG) can attenuate GvHD but may increase infection and relapse risks. ATG-Fresenius (ATG-F) at a dose of 60 mg/kg was standard GvHD prophylaxis in unrelated donor hematopoietic stem cell transplantation (HSCT) at our institution. We changed to an incremental reduced dose regimen of 35 mg/kg...
Alternative Titles
Full title
Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogeneic stem cell transplantation
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1765945941
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1765945941
Other Identifiers
ISSN
0268-3369,1476-5365
E-ISSN
1476-5365
DOI
10.1038/bmt.2015.148
